Tarsus Pharmaceuticals Inc Ordinary Shares TARS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TARS is a good fit for your portfolio.
News
-
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
-
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
-
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
-
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
-
Tarsus to Participate at Upcoming Investor Conferences
-
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
-
Tarsus Announces Pricing of $100.0 Million Public Offering
-
Tarsus Announces Proposed $100.0 Million Public Offering
Trading Information
- Previous Close Price
- $38.24
- Day Range
- $37.86–39.48
- 52-Week Range
- $12.57–42.50
- Bid/Ask
- $28.50 / $40.81
- Market Cap
- $1.46 Bil
- Volume/Avg
- 624,353 / 702,628
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.32
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 244
- Website
- https://www.tarsusrx.com
Comparables
Valuation
|
Metric
|
TARS
|
PNT
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 11.36 | — |
Price/Book Value | 5.25 | 3.12 | 4.61 |
Price/Sales | 28.32 | 5.50 | 1,631.75 |
Price/Cash Flow | — | 13.90 | — |
Price/Earnings
TARS
PNT
CRNX
Financial Strength
|
Metric
|
TARS
|
PNT
|
CRNX
|
|---|---|---|---|
Quick Ratio | 7.76 | 9.01 | 17.59 |
Current Ratio | 8.01 | 9.14 | 17.72 |
Interest Coverage | −43.93 | — | — |
Quick Ratio
TARS
PNT
CRNX
Profitability
|
Metric
|
TARS
|
PNT
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | −49.27% | 20.67% | −33.04% |
Return on Equity (Normalized) | −62.79% | 23.56% | −37.88% |
Return on Invested Capital (Normalized) | −58.38% | 23.38% | −39.10% |
Return on Assets
TARS
PNT
CRNX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yssklcqlw | Ggp | $586.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fvzyvdqhv | Qcvkwf | $115.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ztszyqkrl | Rxxgxtd | $108.2 Bil | |
MRNA
| Moderna Inc | Jkgvbrbt | Mqcz | $54.0 Bil | |
ARGX
| argenx SE ADR | Zqsbnfdm | Pvbm | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Gbgfjntm | Gzvk | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fmbgzzgsf | Sqvft | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jftdfqc | Smkgh | $14.6 Bil | |
INCY
| Incyte Corp | Vnnlfpwb | Ystjcv | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xppnhpqgj | Ykbbwft | $12.3 Bil |